New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers Guidance for Industry - Draft Guidance
FDA-2024-D-4388-0002Other
Comments
1
Last activity May 28, 2026
Deadline
--
Net supportiSupport minus oppose · campaigns included
+100%
+100% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers Guidance for Industry - Draft Guidance
- Posted
- Mar 4, 2026
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
+100%
Net support
Support1
Aggregates include form-letter campaigns. Excluding them, net support is +100% across organic comments.
Who commented
Breakdown by commenter type.
Advocacy
1
Comments over time
Weekly arrivals, stacked by stance.
Posted Mar 4, 2026
May 25
Support1Oppose0Other0
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Advocacy
100%
0%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Choose up to five.
| Organization | Scope of nci exclusivity |
|---|
1 organization-typed comment could not be identified.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.